User profiles for Anthony Kong
 | Anthony Pak Hin Kong… Communication, Development, and Information Sciences, The University of Hong Kong Verified email at hku.hk Cited by 1935 |
[HTML][HTML] Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised …
H Mehanna, M Robinson, A Hartley, A Kong, B Foran… - The Lancet, 2019 - thelancet.com
Background The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer,
a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth …
a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth …
Adjuvant radiotherapy for stage I endometrial cancer
A Kong, N Johnson, HC Kitchener… - Cochrane Database of …, 2012 - cochranelibrary.com
Background This is an updated version of the original Cochrane review published in Issue 2,
2007. The role of radiotherapy (both pelvic external beam radiotherapy (EBRT) and vaginal …
2007. The role of radiotherapy (both pelvic external beam radiotherapy (EBRT) and vaginal …
[HTML][HTML] WEE1 inhibitor: clinical development
A Kong, H Mehanna - Current oncology reports, 2021 - Springer
Purpose of Review WEE1 inhibitor has been shown to potential chemotherapy or radiotherapy
sensitivity in preclinical models, particularly in p53-mutated or deficient cancer cells …
sensitivity in preclinical models, particularly in p53-mutated or deficient cancer cells …
[HTML][HTML] A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG …
…, P Specenier, S Rottey, J Guigay, A Kong… - European Journal of …, 2021 - Elsevier
Purpose Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
[HTML][HTML] The expanding role of radiosurgery for brain metastases
Stereotactic radiosurgery (SRS) has become increasingly important in the management of
brain metastases due to improving systemic disease control and rising incidence. Initial trials …
brain metastases due to improving systemic disease control and rising incidence. Initial trials …
[HTML][HTML] Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
…, B Jasani, LJ Jones, TJ Key, CC Kirwan, A Kong… - Breast Cancer …, 2013 - Springer
Introduction Breast cancer remains a significant scientific, clinical and societal challenge.
This gap analysis has reviewed and critically assessed enduring issues and new challenges …
This gap analysis has reviewed and critically assessed enduring issues and new challenges …
Which outcomes are most important to people with aphasia and their families? An international nominal group technique study framed within the ICF
Purpose: To identify important treatment outcomes from the perspective of people with
aphasia and their families using the ICF as a frame of reference. Methods: The nominal group …
aphasia and their families using the ICF as a frame of reference. Methods: The nominal group …
Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis
A Kong, N Johnson, HC Kitchener… - Journal of the National …, 2012 - academic.oup.com
Background The role of adjuvant radiotherapy in stage I endometrial cancer has changed in
recent years. This updated Cochrane systematic review aimed to reexamine the efficacy …
recent years. This updated Cochrane systematic review aimed to reexamine the efficacy …
[HTML][HTML] Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
…, MJ Duffy, N O'Donovan, J Crown, A Kong - Oncotarget, 2013 - ncbi.nlm.nih.gov
Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast
cancer patients. However, a significant proportion of HER2-positive patients are either …
cancer patients. However, a significant proportion of HER2-positive patients are either …
[HTML][HTML] HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer
Herceptin (trastuzumab) is used in patients with breast cancer who have HER2 (ErbB2)–positive
tumours. However, its mechanisms of action and how acquired resistance to Herceptin …
tumours. However, its mechanisms of action and how acquired resistance to Herceptin …